Toggle sidebar
定价
登录
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
REGENXBIO(US:RGNX)
Barrons
·
2026-08-24 20:39
临床试验安全性事件 - Regenxbio公司报告在RGX-121(针对Hunter综合征的试验性疗法)的临床试验中,发现患者脊柱出现结节和肿块 [1]
REGENXBIO-Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial - Reportify